Stephanie Barbara Schatz, Christoph Jüngst, Verena Keitel‐Anselmo, Ralf Kubitz, Christina Becker, Patrick Gerner, Eva‐Doreen Pfister, Imeke Goldschmidt, Norman Junge, Daniel Wenning, Stephan Gehring, Stefan Arens, Dirk Bretschneider, Dirk Grothues, Guido Engelmann, Frank Lammert, Ulrich Baumann – 22 March 2018 – Genetic variants in the adenosine triphosphate‐binding cassette subfamily B member 4 (ABCB4) gene, which encodes hepatocanalicular phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid‐as

Uttara Saran, Maria Guarino, Sarai Rodríguez, Cedric Simillion, Matteo Montani, Michelangelo Foti, Bostjan Humar, Marie V. St‐Pierre, Jean‐François Dufour – 22 March 2018 – Regular physical exercise has many beneficial effects, including antitumor properties, and is associated with a reduced risk of developing hepatocellular carcinoma (HCC). Less is known about the impact of exercise on HCC growth and progression.

Narjeet S. Khurmi, Yu‐Hui Chang, D. Eric Steidley, Andrew L. Singer, Winston R. Hewitt, Kunam S. Reddy, Adyr A. Moss, Amit K. Mathur – 15 March 2018 – Cardiovascular disease (CVD) is a leading cause of post–liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals.

Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun – 15 March 2018 – According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate‐ to advanced‐stage (BCLC stage B/C) HCC to determine the current evidence.

Elizabeth Carey – 15 March 2018

Lisa B. VanWagner, Fasiha Kanwal – 14 March 2018 – With the passage of the Affordable Care Act followed by the physician payment reform, there is an urgent need to better understand the complex relationships between structure (including incentives), processes, and outcomes of health care and, based on this understanding, identify interventions that can ensure delivery of high‐value care to patients with liver disease. As hepatologists, how do we systematically address these issues and ensure that we provide high‐value care to our patients?

Tiong Y. Lim, Enoka Gonsalkorala, Mary D. Cannon, Stella Gabeta, Leonie Penna, Nigel D. Heaton, Michael A. Heneghan – 14 March 2018 – Liver transplantation (LT) is a successful treatment for both acute liver failure and end‐stage liver disease. The number of women of reproductive age undergoing LT is increasing. Pregnancy outcomes are favorable, but there is still a lack of prognostic markers. We aimed to identify factors predictive of adverse pregnancy outcomes in LT recipients.

Chen Qu, Dandan Zheng, Sai Li, Yingjun Liu, Anna Lidofsky, Jacinta A. Holmes, Jianning Chen, Lu He, Lan Wei, Yadi Liao, Hui Yuan, Qimeng Jin, Zelong Lin, Qiaoting Hu, Yuchuan Jiang, Mengxian Tu, Xijun Chen, Weiming Li, Wenyu Lin, Bryan C. Fuchs, Raymond T. Chung, Jian Hong – 14 March 2018 – Spleen tyrosine kinase (SYK) plays a critical role in immune cell signaling pathways and has been reported as a biomarker for human hepatocellular carcinoma (HCC). We sought to investigate the mechanism by which SYK promotes liver fibrosis and to evaluate SYK as a therapeutic target for liver fibrosis.

Cynthia A. Moylan, Manal F. Abdelmalek – 13 March 2018

Narayan Ramamurthy, Emanuele Marchi, M. Azim Ansari, Vincent Pedergnana, Angela Mclean, Emma Hudson, STOP HCV consortium, Rory Bowden, Chris C.A. Spencer, Eleanor Barnes, Paul Klenerman – 13 March 2018 – New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat, including those with cirrhosis or infected with HCV genotype 3.